Seven US medical centers to acquire Elekta’s new Leksell Gamma Knife Icon brain radiosurgery system

ATLANTA, October 12, 2015 – Patients in the United States with brain cancer or
any of a range of other neurological disorders will soon have access to the most
sophisticated system for the radiosurgical treatment of their disease. Seven
centers are first in the nation to order Leksell Gamma Knife® Icon™, which
features the first integrated stereotactic cone beam CT imaging,  online
adaptive dose evaluation and planning enabling the most accurate delivery of
frameless and frame-based treatments. Icon was designed to enable treatment of
virtually any target in the brain – from refractory essential tremor and complex
vascular malformations to multiple metastases – while delivering the lowest dose
to healthy tissues.
The first US Icon installations will be: Emory St. Joseph’s Hospital (Atlanta,
Georgia), University of Virginia Health System (Charlottesville, Virginia),
Roswell Park Cancer Institute (Buffalo, New York), The University of Texas MD
Anderson Cancer Center (Houston, Texas), Miami Cancer Institute at Baptist
Health South Florida (Miami, Florida), University of Pittsburgh Medical Center
(UPMC, Pittsburgh, Pennsylvania) and Gamma Knife of Spokane (Spokane,
Washington).

Gamma Knife Icon is the sixth generation of the company’s Leksell Gamma Knife
system, a technology that has been in use worldwide and continually evolving
since the 1980s. In the United States, Gamma Knife is the most commonly used
radiosurgery platform for the brain1, is the most clinically proven technology
for cranial indications2 and offers the lowest dose to normal tissues 3-7.

“UPMC has partnered with Elekta since the first 201-source Gamma Knife – the
fifth worldwide – was installed in Pittsburgh in 1987,” says L. Dade Lunsford,
MD, Lars Leksell Professor of Neurosurgery at UPMC and consultant to Elekta.
“Each of the six generations of Gamma Knife has resulted in improvements in the
outcomes and efficiency of brain radiosurgery, and we have pioneered their use.
We are pleased to add the first US complete Gamma Knife Icon system with
anticipated installation in early 2016. Icon will add new methods of non
-invasive cranial immobilization, while preserving standard immobilization
technologies – used in more than 14,500 patients at UPMC – for patients with
brain tumors and vascular malformations located in critical brain regions.”

According to Peter J. Rossi, MD, Medical Director, Radiation Oncology at Emory
St. Joseph’s Hospital, the upgrade of its Leksell Gamma Knife® Perfexion™ system
to Icon presents new opportunities to treat patients with lesions more suited to
a frameless, multi-session approach.

“Patients with lesions such as small metastases have benefited from the high
precision, reproducibility and targeting ability of our Perfexion system, but
with larger or more critically located tumors it can be better to fractionate
their treatment,” Dr. Rossi explains. “With the Icon system, we will have the
best of all worlds. We can maintain the unparalleled precision to treat tumors
with the lowest possible radiation exposure to healthy tissues, while at the
same time opening up the possibility to confidently treat without the
stereotactic frame over more than a single session. These indications include
acoustic schwannomas and complex meningiomas that may be close to hearing and
visual anatomy, respectively, and large pituitary lesions, for example, that
require the accumulation of a large dose over multiple sessions to protect
healthy brain tissues.”

"Leksell Gamma Knife Icon establishes a new international standard for precision
radiosurgery and fractionated radiotherapy for targets within the brain and head
and neck,” adds Christopher M. Lee, MD, Research Director for Gamma Knife of
Spokane and Cancer Care Northwest. “We look forward to the new innovations in
patient comfort, precision and speed of treatment, on-demand adaptability with
regard to patient dose, as well as the novel cutting-edge motion management
features. This technology will be practice-changing for our group, and is a
great enhancement to overall patient care."

“We are pleased that these world-class centers – many of which also have access
to stereotactic linear accelerators – have recognized the value of this latest
generation Gamma Knife system as their system of choice for brain radiosurgery,”
says Bill Yaeger, Elekta’s Executive Vice President, Region North America. “The
unique motion management and imaging technologies in Icon reinforce the level of
precision for which Gamma Knife technology is renowned – making Gamma Knife
microradiosurgery even more accurate for particularly challenging cases.”

To learn more about Leksell Gamma Knife Icon, visit www.careforthebrain.com.

 1.
CMS data through 2013

 2.
Pubmed through June 2015

 3.
Ma L, Petti P, Wang B, et al. (2011) Apparatus dependence of normal brain tissue
dose in stereotactic radiosurgery for multiple brain metastases. J Neurosurg
114(6):1580-1584. doi:10.3171/2011.1.JNS101056.

 4.
Ma L, Nichol A, Hossain S, et al. (2014) Variable dose interplay effects across
radiosurgical apparatus in treating multiple brain metastases. Int J CARS.
Published online: 20 April 2014. doi:10.1007/s11548-014-1001-4

 5.
Descovich M, Sneed PK, Barbaro NM, et al. (2010) A dosimetric comparison between
Gamma Knife and CyberKnife treatment plans for trigeminal neuralgia. J Neurosurg
113:199-206.

 6.
McDonald D, Schuler J, Takacs I, et al. (2014) Comparison of radiation dose
spillage from the Gamma Knife Perfexion with that from volumetric modulated arc
radiosurgery during treatment of multiple brain metastases in a single fraction.
J Neurosurg (Suppl 2) 121:51-59.

 7. Lindquist C, Paddick I. (2007) The Leksell Gamma Knife Perfexion and
comparisons with its predecessors. Neurosurgery 61:ONS-130-ONS-141, doi:
10.1227/01.NEU.0000279989.86544.B6.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on October 12, 2015.
About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,800 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on NASDAQ Stockholm. Website: www.elekta.com.